baber/WOPTO huggingface dataset:
Patent NZ-511221-A (NZ)
Title: Crosslinked conducting polymer composite materials
Inventor: FOULGER STEPHEN H
IPC: C08L23/06
Filed: 1999-10-18
Abstract: A conducting polymer composite that is crosslinked comprises: a) a minor phase material comprising a semicrystalline polymer having a crystallinity from 30% to 80% and having a solubility parameter dA, in Joules per cubic centimeter; b) a conducting filler material dispersed in the minor phase material in an amount which is at or just exceeds the percolation threshold and sufficient to generate a continuous conducting network in the minor phase material, and c) a major phase material having a solubility parameter dB in Joules per cubic centimeter forming a conducting polymer composite having separate phases which meets the following criteria for immiscibility 7.0³ (dA-dB) ³0. The major phase material is a polymer which when mixed with the minor phase material will not engage in electrostatic interactions that promote miscibility.  The major phase material has the minor phase material dispersed therein in an amount, which is at or just exceeds the percolation threshold and sufficient to generate a continuous conducting network in the major phase material. The conducting filler can be carbon black, graphite, metallic particles, carbon fibers, intrinsically conducting polymers, fullerenes, carbon nanotubes and mixtures thereof.
Patent NZ-513214-A (NZ)
Title: Pressure limiting valve
Inventor: BOLUS ROBERT NICHOLAS EDWARD
IPC: F16K17/30
Filed: 1999-12-23
Abstract: A valve seal assembly (5) for a pressure limiting valve (1). The valve seal assembly includes a support member (32) and sealing means in the form of a cup washer (33) engaged on the support member by engagement means (34), the engagement means engaging the sealing means by peripheral portions only.
Patent NZ-513219-A (NZ)
Title: Methods for conditional transgene expression and trait removal in plants
Inventor: YADAV NERENDRA S
IPC: C07K17/08
Filed: 2000-11-16
Abstract: Disclosed are constructs for the conditional or regulated expression or excision of transgenes in plants using site-specific recombinase systems. The constructs comprise a variety of constitutive, inducible, tissue specific or developmental stage-specific promoters operably linked to either a transgene or the elements of one or more site-specific recombinase system. By matching promoters, responsive to various inducers, plant tissues or plant developmental states with the recombinase systems, stop fragments and transgenes, virtually any trait may be expressed or excised at any plant development stage or in any plant generation.
Patent NZ-517849-A (NZ)
Title: Centralized document management system
Inventor: HAJMIRAGHA MIR
IPC: G06F17/30
Filed: 2000-09-13
Abstract: A system for allowing predesignated users at remotely located computer-based systems (22) to perform document management. Components of the system include public data network (24), a publication facility, a remote storage facility (28) and a document manager computer-based system (21). The document manager computer-based system (21), the publication facility, the remote storage facility (28) are coupled to the computer-based systems (22) used by the predesignated users over the public data network (24). The system allows authorized users from remote locations to perform secure document collaboration, share and archive documents, context index documents, digitally notarize documents, electronically file documents and publish documents.
Patent NZ-525421-A (NZ)
Title: Method of treating cancer by determining the presence of the disease condition using an assay to determine the binding pattern of immobilised immunoglobulins
Inventor: CHRISTOPHERSON RICHARD IAN
IPC: G01N33/574
Filed: 1999-12-23
Abstract: Described is a method for identifying a molecular profile that is determinative of a disease or condition in a subject. The method comprising; (a) contacting a biological sample comprising molecules of the molecular profile from a subject known to have the disease or condition with an immobilized array containing differential potential binging partners of the molecules; (b) determining the level of the binding to the molecules to each of the binding partners; (c) repeating steps (a) and (b) with a number of subjects known to have the disease or condition; and (d) consolidating the results obtained from all the subjects to determine a common pattern of binding for the disease or condition when compared with a negative control. In this way a consensus molecular profile that is determinative of the presence or absence of the disease or condition can be established (62) Divided out of 512472
Patent NZ-526284-A (NZ)
Title: mmunotherapeutic combinations comprising antibody/vaccine combinations for the treatment of tumors dependant on tyrosine kinase receptors for growth
Inventor: PEREZ RODRIGUEZ ROLANDO
IPC: A61K39/00
Filed: 2001-12-06
Abstract: Disclosed are immunotherapeutic combinations and treatment methods to prevent the growth of tumor cell and/or eliminate said cells. The methods disclosed in the invention are based on the blockage of kinase protein receptors in tyrosine residues (RTK) and the ligands for said receptors. Particularly described are immunotherapeutic combinations that block the RTK receptors and/or their ligands by combining active and/or passive immunotherapy against said receptors. The methods disclosed can be used in patients with different clinical states of tumors of epithelial origin which overexpress said receptors. The active and passive immunotherapeutic combination can be used simultaneously or sequentially depending on whether the therapeutic method is being used in patients with an advanced disease state or as adjuvant therapy.
Patent NZ-528506-A (NZ)
Title: Solar-based power generating system
Inventor: HEBERT THOMAS H
IPC: F24S10/95
Filed: 2002-03-08
Abstract: A solar-based power generating system (10) including an electrical alternator (32) or generator for generating electrical power in which the alternator or generator is driven by a refrigerant circulating through a closed-loop heat transfer system including an evaporator (12) exposed to solar energy and a condenser (14) disposed within a large heat sink such as a body of water.
Patent NZ-530579-A (NZ)
Title: Highly selective NK-1 receptor (substance P) antagonists
Inventor: BALLARD THERESA MARIA
IPC: A61P25/24
Filed: 2002-07-26
Abstract: The compound of formula 1 is described wherein R1 is hydrogen or fluoro. A pharmaceutical composition comprising the compound is useful for the treatment of NK-1 receptor related diseases such as migraine, arthritis, asthma, bronchial hyperreactivity, inflammatory bowel disease, Parkinson's disease, anxiety, depression, pain, headache, Alzheimer's disease, multiple sclerosis, oedema, allergic rhinitis, Crohn's disease, ocular injury, ocular inflammatory disease, psychosis, motion sickness, induced vomiting, emesis, urinary incontinence, psychoimmunologic or psychosomatic disorders, cancer, withdrawal symptoms of addictive drugs from opiates or nicotine, traumatic brain injury, benign prostatic hyperplasia.
Patent NZ-530818-A (NZ)
Title: Use of a LIVP strain of vaccina virus in the preparation of a composition for detection of a tumor
Inventor: SZALAY ALADAR A
IPC: C12N1/21
Filed: 2002-07-31
Abstract: Disclosed is the use of an LIVP strain of vaccinia virus in the preparation of a composition for detection of a tumour, tumour tissue, cancer or metastasis in a subject, wherein: (1) the virus comprises DNA encoding a detectable protein or protein capable of inducing a detectable signal; (2) the virus is capable of replicating in the subject; (3) the virus is recognized by the immune system of the subject; (4) the virus is not pathogenic or is attenuated.
Patent NZ-531894-A (NZ)
Title: Laminated zeolite composite and method for preparation thereof
Inventor: MORI NOBUHIKO
IPC: B01D53/22
Filed: 2002-09-12
Abstract: A laminated zeolite composite is disclosed which comprises a mean fluorescence intensities (MFI) membrane film being composed of a MFI type of zeolite and having a SiO2/Al2O3 molar ratio of 40 to 100 and a porous substrate being composed of a MFI type of zeolite and having a SiO2/Al2O3 molar ratio of 20 to 400 and the MFI membrane film is formed on the substrate. The laminated zeolite composite combines excellent separation characteristics and high permeation performance capability.
Patent NZ-532006-A (NZ)
Title: Tooth tip, typically for wood hogging apparatus, with tapered bottom face configured to interact with complementary base portion top face
Inventor: SHARP RODNEY WARWICK
IPC: B28D1/18
Filed: 2004-03-29
Abstract: Disclosed is a replaceable tooth arrangement for use in grinding discs such as used in wood hoggers and comminuting equipment. A preferred tooth arrangement comprises two end to end adjacent tip portions, or a tip portion end to end with a complementary base portion. The contacting faces of the portions are tapered so that tightening together creates a resultant outward movement which tightens them against the walls of a retaining aperture in a disc or disc section. Alternatively or additionally a connection element interacts with a wedge keeper which causes a similar outward component in the keeper and tip portion, tightening them against the walls of a retaining aperture as the connection element is tightened.
Patent NZ-534034-A (NZ)
Title: Synthesis of ecteinascidin compounds which have a quinone ring for ring E which are active as anti-cancer agents
Inventor: CUEVAS CARMEN
IPC: C07D515/18
Filed: 2003-02-04
Abstract: Ecteinascidin compounds of formula (Ab) with a quinone ring for ring E are disclosed, wherein the variables are as defined in the specification. These ecteinascidin compounds are suitable for use as anti-cancer agents. Related processes and compounds are also disclosed.
Patent NZ-536014-A (NZ)
Title: Pyrrolo-triazine aniline compounds useful as kinase inhibitors for treating inflammatory disorders
Inventor: DYCKMAN ALARIC
IPC: B01F25/90
Filed: 2003-04-15
Abstract: Pyrrolo-triazine aniline compounds having the formula (I), and pharmaceutically acceptable salts, prodrugs, and solvates thereof, that are useful as kinase inhibitors are disclosed, wherein R1, R2, R3, R4, R5, R6, m, X and Z are as described in the specification. These compounds are suitable for an treating inflammatory disorder selected from asthma, adult respiratory distress syndrome, chronic obstructive pulmonary disease, chronic pulmonary inflammatory disease, diabetes, inflammatory bowel disease, osteoporosis, psoriasis, graft vs. host rejection, atherosclerosis, and arthritis including rhematoid arthritis, psoriatic arthritis, traumatic arthritis, rubella arthritis, gouty arthritis and osteoarthritis.
Patent NZ-537650-A (NZ)
Title: Drive apparatus utilising forces between rotating magnets on respective shafts, with additional mass on driven shaft(s) to increase rotational inertia
Inventor: FRENCH ANDREW BOYD
IPC: H02K1/00
Filed: 2001-10-11
Abstract: Apparatus for inducing drive (10) as shown includes a primary drive shaft (12) and four secondary drive shafts (14), the primary shaft (12) and secondary shafts (14) each fitted with magnetic means typically in the form of permanent magnets (16) which are oriented such that when the primary shaft (12) is rotated the secondary shafts (14) are caused to rotate due to attractive or repulsive magnetic forces. The primary shaft (12) is connected to and rotated by a rotational energy source such as a motor (8) powered by electricity or a battery, although any source of energy to cause rotation of the primary shaft is within the scope of the invention. Each secondary shaft (14) can be fitted with a second magnetic means typically in the form of two annular magnetic discs (26, 28) oriented so as to vertically support the weight of the shaft (14) (and any attachments/fittings thereto) above the alternating or generating device (22). The discs can be arranged to provide either an attractive or repulsive magnetic force between them.
Patent NZ-539229-A (NZ)
Title: Heparin-derived polysaccharide mixtures, preparation thereof and pharmaceutical compositions containing same
Inventor: BIBEROVIC VESNA
IPC: C08B37/00
Filed: 2003-10-08
Abstract: A mixture of sulfated oligosaccharides consisting of heparin-derived polysaccharide mixtures having an average molecular weight of 1500 to 3000 daltons and an anti-Xa activity/anti-IIa activity ratio higher than 30, their preparation method and pharmaceutical compositions containing same are disclosed.
Patent NZ-541670-A (NZ)
Title: An apparatus and method for the manufacture of roof cladding elements
Inventor: NEWTON DAVID ISAAC
Filed: 2005-08-05
Abstract: A cutting assembly for cutting a longitudinal strip of material includes a support means adapted to support a cutting means in a position in a position to receive the longitudinal strip of material. The cutting means is rotatable about a vertical axis of rotation relative to the support means to cut the material at pre-determined angles.
Patent NZ-543360-A (NZ)
Title: Method for billable timekeeping with conflict resolution and discount features
Inventor: WALKER DAVID ANDREW
Filed: 2005-11-02
Abstract: A method and computer program for billable timekeeping accepting inputs for start time, end time, an identifier, and/or a billable percentage. The inputs may be manually entered or automatically derived from the activity itself, for example, a start time may be automatically recorded when a particular type of file is opened for editing, and an end time recorded when it is closed. The event identifier could be the file name, the author identifier, or a client identifier. The system detects a time overlap between events and initiates conflict resolution, offering various options to correct the overlap.
Patent NZ-545629-A (NZ)
Title: Foam nozzle
Inventor: BOTICKI JOHN A
IPC: B05B7/00
Filed: 2004-08-25
Abstract: A foam producing nozzle (10) is disclosed for attachment to a spray nozzle (20) which is readily attached and removed therefrom. The foam producing nozzle (10) has air channels which do not lend themselves toward leaking. The dilution rate of the chemical concentrate is not affected by the foam producing nozzle (10).
Patent NZ-546111-A (NZ)
Title: Crystal of sulfonamide-containing indole compound and process for producing the same
Inventor: TAKAHASHI KEIKO
IPC: C07D209/42
Filed: 2004-09-01
Abstract: Disclosed is a crystalline form (Form C) of N-(3-cyano-4-methyl-1H-indol-7-yl)-3-cyanobenzenesulfonamide having a diffraction peak at a diffraction angle (2 theta +/- 0.2 degrees) of 11.4 degrees in a powder X-ray diffraction, and a crystalline form (Form A) N-(3-cyano-4-methyl-1H-indol-7-yl)-3-cyanobenzenesulfonamide hydrate having a diffraction peak at a diffraction angle (2 theta +/- 0.2 degrees) of 8.5 degrees in a powder X-ray diffraction. Also disclosed are processes for their preparation.
Patent NZ-548017-A (NZ)
Title: Solid dosage form
Inventor: ALEX RAINER
IPC: A61K9/20
Filed: 2005-01-13
Abstract: Disclosed is a solid dosage form comprising a predefined magnetic pattern.
Patent NZ-550848-A (NZ)
Title: Method for safely logging onto a technical system
Inventor: SCHLUDERBACHER HELMUT
IPC: G06F21/36
Filed: 2005-03-31
Abstract: The invention relates to a method for safely logging onto a technical system by means of a user code stored in the system. The method comprises, displaying a selection code consisting of a plurality of graphics, displaying a response code consisting of a plurality of graphics. The method then comprises selecting the graphic of the response code, which has characteristics corresponding to the stored user code that are clearly associated with at least one characteristic of at least one graphic of the selection code. Finally the method comprises checking the selected graphic of the response code according to the stored user code, and when the selected graphic of the response code correlates with the stored user code, the technical system can be logged onto.
Patent NZ-552984-A (NZ)
Title: Modified pyrimidine glucocorticoid receptor modulators
Inventor: CLARK ROBIN D
IPC: A61P25/24
Filed: 2005-06-29
Abstract: Disclosed is a pyrimidine-2,4-dione of formula (I), wherein m an n are integers independently selected from 0 and 2 and the further substituents are defined as per the specification. Also disclosed is the use of said compound for the manufacture of a medicament for the treating a disorder or condition through modulating a glucocorticoid receptor, a pharmaceutical composition comprising said compound and an in vitro method comprising said compound.
Patent NZ-573646-A (NZ)
Title: Single-chain multivalent binding proteins with effector function
Inventor: THOMPSON PETER ARMSTRONG
IPC: A61P31/00
Filed: 2007-06-12
Abstract: Provided is a multivalent single-chain binding protein comprising from amino to carboxy terminus: a. a first binding domain derived from an immunoglobulin-like molecule or the variable regions of an immunoglobulin; b. a constant sub-region comprising an immunoglobulin CH2 domain and a CH3 domain; c. a scorpion linker, wherein said scorpion linker comprises an amino acid sequence derived from a hinge of an immunoglobulin or immunoglobulin-like molecule or an extracellular stalk region of a type 2 membrane protein in the C-type lectin family; and d. a second binding domain derived from an immunoglobulin-like molecule or the variable regions of an immunoglobulin.
Patent NZ-578111-A (NZ)
Title: Cylindrical or conical filter with helical scraper for residue cake
Inventor: MORGAN GREGORY RICHARD
IPC: B01D29/35
Filed: 2010-07-01
Abstract: A filter particularly suitable for filtering grape and similar juices and liquids includes a filter chamber 12 with a fluid inlet 15 into which the liquid to be filtered is pumped to pressurize the chamber and a fine screen filter element 23 around the cylindrical wall of the chamber. The filtered liquid passes through the screen and is collected at 19 and the residue is wiped from the inside of the filter screen and toward the residue outlet 45 that is at the other end of the filter chamber from the inlet. The helical wiper 25 is provided with blades to wipe the residue toward the residue outlet and impeller blades to direct the fluid in the chamber back toward the inlet in a counter-flow from the flow from the pump at the inlet to provide for efficient filtering of the juice without having to stop and clear the filter screen.
Patent NZ-579751-A (NZ)
Title: Oocyte retrieval needle comprising first and second tubular regions where the second has a larger diameter than the first.
Inventor: HAGBY URBAN
IPC: A61B17/435
Filed: 2008-01-24
Abstract: A vaginal oocyte retrieval needle (632) is disclosed comprising a first tubular (634) region in fluid communication with a second tubular region (636). The first tubular region (634) comprises a leading end (638) for insertion into a subject and the second tubular region (636) comprises a trailing end (640) for fluid communication with a means for receiving a fluid. The first tubular region (634) outer diameter and inner diameter is less than the respective outer and inner diameter of the second tubular region (636). The second tubular region (636) has a length (X) adapted to traverse a vagina to reach a tissue in which an oocyte is located. The first tubular region (634) has a length (Y) adapted to penetrate the tissue in order to reach the oocyte without the second tubular region (636) penetrating the tissue.
Patent NZ-587397-A (NZ)
Title: Stabilization of dehydrogenases using stable chemically modified coenzymes
Inventor: HEINDL DIETER
IPC: C12N9/96
Filed: 2009-02-19
Abstract: Disclosed is a method for stabilizing a coenzyme dependent enzyme, characterized in that the enzyme is stored in the presence of the coenzyme, said coenzyme being a stable coenzyme chemically modified by comparison to, and having a higher stability than, the native coenzyme. Also disclosed is a coenzyme dependent enzyme which is stabilized with the coenzyme, said coenzyme being a stable coenzyme chemically modified by comparison to, and having a higher stability than, the native coenzyme, characterized in that it shows on storage for at least 2 weeks at a temperature of at least 20 degrees C, where appropriate with high humidity and without a drying reagent, a decline in the enzymatic activity of less than 50% compared with the initial level, wherein the enzyme is a mutated glucose dehydrogenase and the mutated glucose dehydrogenase has an increased thermal or hydrolytic stability compared with the corresponding wild-type glucose dehydrogenase.
Patent NZ-591492-A (NZ)
Title: Human notch3 based fusion proteins as decoy inhibitors of notch3 signaling
Inventor: KITAJEWSKI JAN
IPC: A61K39/00
Filed: 2009-08-21
Abstract: Disclosed is a fusion protein comprising a signal peptide, EGF repeats 1-X of the extracellular domain of human Notch3 receptor protein wherein X is any integer from 12 to 34, and an Fc portion of an antibody bound thereto, wherein the signal peptide is the signal peptide of Notch3 or IgG Heavy Chain. Further disclosed is a fusion protein comprising a signal peptide, EGF repeats 1-X of the extracellular domain of human Notch3 receptor protein wherein X is any integer from 1 to 10, and an Fc portion of an antibody bound thereto, wherein the signal peptide is the signal peptide of Notch3 or IgG Heavy Chain. Further disclosed is a fusion protein comprising a signal peptide, at least 12 EGF repeats of the extracellular domain of human Notch3 receptor, and an Fc portion of an antibody bound thereto, wherein the signal peptide is the signal peptide of Notch3 or IgG Heavy Chain. Further disclosed is a fusion protein comprising a signal peptide, EGF repeats of the extracellular domain of human Notch3 receptor protein, wherein at least 12 EGF repeats are present, and an Fc portion of an antibody bound thereto, wherein the signal peptide is the signal peptide of Notch3 or IgG Heavy Chain.
Patent NZ-591569-A (NZ)
Title: Modification of flavonoid biosynthesis in plants with transparent testa 2
Inventor: MOURADOV AIDYN
IPC: A01H5/00
Filed: 2006-07-19
Abstract: Disclosed is a substantially purified or isolated nucleic acid or nucleic acid fragment encoding TRANSPARENT TESTA 2 (TT2) from a clover (Trifolium), species. Further disclosed are substantially purified or isolated TT2 polypeptides from a clover (Trifolium), species.
Patent NZ-606679-A (NZ)
Title: Formulations of 14-epi-analogues of vitamin d and cmc
Inventor: Delansorne Rémi
IPC: A61K47/38
Filed: 2011-07-13
Abstract: The present disclosure provides formulations of a 14-epi-analogues of vitamin D, being inecalcitol (19-nor-9,10-seco-14bHcholesta-, 5(Z),7(E)-dien-23-ino-1a,3b,25-triol-23-yne), with carboxymethylcellulose, providing improved absorption profile. the formulations show an improved absorption of inecalcitol over the formulation in medium chain triglyceride. The formulation is useful for the prevention and/or treatment of rickets, osteoporosis, osteomalacia, psoriasis, autoimmune diseases such as multiple sclerosis or type I diabetes, hyperparathyroidism, benign prostate hyperplasia, any type of cancer or any vitamin D associated disease.